DOCSLIB.ORG

Title 54 Pt Arial, Two Line Maximum

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Title 54 Pt Arial, Two Line Maximum Benign Hematology Consult Cases Annemarie E. Fogerty, M.D. Clinical Director, Hematology Director, Reproductive Hematology Co-Medical Director, Anticoagulation Management Services September 2019 • No financial disclosures relevant to this presentation Case 1: 42yoF presenting with shortness of breath and productive cough Initial presentation • Vitals: T 99.2, HR 133, BP 145/75, RR 33, 92% sat on RA, improves to 95% with 2L 3 hours into presentation… Admitted to MICU • Vitals: T 100.8 , HR 140, BP 187/45, RR 45, 92% sat on 100% FiO2, 60L high-flow face mask 3 hours into MICU admission (6 hours from presentation) … • Vitals: Persistently febrile, T up to 105 • Respiratory status: O2 sat 80’s despite paralytics/vent adjustment, FiO2 1.0, inhaled flolan Case 1, continued: 4am in the MICU • Extracorporeal membrane oxygenation (ECMO) is initiated ECMO has been shown to improve patient survival in acute respiratory distress, but associated with substantial hematologic derangements Lancet 2009; 374:1351 How does ECMO work? • An artificial lung (membrane oxygenator) oxygenates blood, which is returned to the circulation via the vein (VV) or artery (VA) – VV: artificial lung is in series with native lung, replacing lung function – VA: artificial lung is in parallel with native lung, replacing both heart and lung function • Blood exposure to the large ECMO circuit area – Initiates the contact factor pathway – Activates platelets – Induces an inflammatory response • Anticoagulation is necessary to prevent clotting the circuit – Intensity of anticoagulation, PTT/ACT have not correlated with clinical outcomes, or risk for bleeding/thrombosis Brodie D, Bacchetta M. N Engl J Med 2011;365:1905-1914. In a patient managed with UFH on ECMO, the optimal laboratory test to assess the degree of anticoagulation is: A. PTT, traditional therapeutic target B. ACT, target 180-220s C. Anti-Xa D. Thrombin time PANEL QUESTION • Optimal laboratory test to assess degree of anticoagulation in a patient managed with ECMO and UFH ACT PTT • Rapid, point of care test • Widely available • Most useful at very high heparin • Provider familiarity concentrations (when PTT is >assay) • Nonspecific to heparin • Nonspecific to heparin • Influenced by factor/fibrinogen deficiency, • Influenced by hypothermia, lupus antiphospholipid antibody thrombocytopenia, impaired platelet function, factor/fibrinogen deficiency Anti-Xa Thrombin time • Direct measure of heparin effect • Exquisitely sensitive to presence of heparin, thus not an appropriate measure • Can be influenced by hyperlipidemia and for therapeutic heparin levels hyperbilirubinemia • Not widely/routinely available 12 3.7 > 32% < 126K. PTT 89.6, ACT 202s The ECMO circuit continues to clot, despite increasing UFH doses. The next best intervention is: A. Initiate antiplatelet therapy B. Initiate FFP therapy C. Transfuse RBCs D. Assess hypercoagulable panel E. Switch to alternative anticoagulant Case 1, continued • Day 7 into use of ECMO circuit, a persistently falling platelet count is appreciated: – D1 123 -> D2 116 -> D3 108 -> D4 87 -> D5 64 (transfused platelets) -> D6 88 -> D7 57 The next best intervention is: A. Transfuse additional platelets B. Discontinue UFH and reassess platelet count in 12H C. Discontinue UFH in favor of an alternative anticoagulant D. Alternate antibiotic regimen in favor of less BM suppressive agents Case 1b, continued • Decreasing platelet count concurrent to heparin therapy merits consideration of heparin-induced thrombocytopenia (HIT) – In this case the 4T test predicted high probability; PF4 Ab returned positive (OD >2) – Patient was transitioned to bivalirudin (direct thrombin inhibitor) via standard PTT sliding scale • Should bivalirudin have been used from the start? – Would have avoided the thrombotic complications of HIT complications … BUT • Same challenges of PTT monitoring • Unlike heparin (and warfarin), DTIs do not inhibit the contact pathway (of particular concern with use of ECMO) Case 1, summary • ECMO was decannulated on hospital day 18 • Patient continued to recover and was ultimately discharged to rehab on day 27 • Surveillance for thrombosis in HIT revealed R femoral vein thrombosis: – Continued on DTI until ECMO was decannulated – Transitioned to warfarin once platelet count was >150K (intended for 6 month course for provoked event) • Total blood component support during hospitalization: – 28 RBCs, 21 platelet doses, 36 FFP, 24 cryo A word on contact pathway inhibitors • The goal of anticoagulation is to attenuate thrombosis without perturbing hemostasis • FXIa contributes to VTE/CAD, while contributing minimally to hemostasis • Attempt to block FXIIa mediated FXI activation WIHOUT inhibiting FXI’s activation by thrombin may serve as “the perfect model” of anticoagulation Buller HR; Weitz JI. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. NEJM. Jan 2015. VTE Bleeding FXI-ASO 27% 3% 200mg sc* FXI-ASO 4% 3% 300mg sc* Enoxaparin 30% 8% 40mg sc qd** * Started 36d before surgery ** Started peri-operatively Lorentz, CU; Gailani D. Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arter , Thromb, Vasc Biol. 39(4). 2019 PANEL QUESTION • Would you consider drugs that specifically inhibit the contact pathway as the “ideal” anticoagulants for ECMO patients? Case 2 37yoF G3P0020 at 32w referred for platelets of 68K and no bleeding. (WBC 13.9 > HCT 27.6 < Plt 68K, MCV 78) • Reports general malaise and “coming down with a cold” mild headache. No cough or fevers. No GI complaints. • PMH: No bleeding/bruising. Miscarriages: weeks 6 and 11 • FH: no heme disorders or malignancies • Exam: Well appearing, afebrile. 128/90, HR 104, RR 26 – no mucocutaneous bleeding, bruising, enlarged nodes or rash – Soft flow murmur; lungs CTA without wheeze – Gravid, no HSM palpated – Trace pedal edema bilaterally; no palpable cords Case 2, data (13.9>27.6<68, MCV 78) – ALT/AST 48/38, Alk Phos 194 – TB/DB 1.9/0.4 – LDH 428 – Haptoglobin < 6 – Reticulocyte count: 3.9% – Bun/Cr 12/0.87 – PT/PTT normal – Iron saturation 9% – +proteinuria Case 2 (13.9>27.6<68, MCV 78) The best next intervention is: A. Initiate plasma exchange B. Initiate eculizumab therapy C. Initiate steroids and rituximab and repeat CBC in 1 week D. Urgent fetal delivery E. Bone marrow biopsy TMA: TTP • 5-10% of all cases of TTP occur in pregnancy (increased VWF production, decreased ADAMTS13 levels) • ADAMTS13 <10% (congenital or acquired) • Usually 2nd/3rd trimesters (can be in 1st) • High risk for IUFD • Treatment: Plasma exchange (PLEX) – Standard therapy for non-pregnant TTP – Close fetal monitoring TMA: aHUS • More typically postpartum; predilection for kidneys – Suspect if MAHA, ADAMTS13 is normal/only slightly reduced • Complement deregulation leading to increased activity of the alternative complement pathway. Can see mutations in: – Complement regulatory proteins: Factor H, Factor I, CD46 – Complement-activating genes: Factor B or C3 • Treatment: – Eculizumab (humanized monoclonal Ab inhibitor of C5, preventing formation of the terminal membrane attack complex) • *case reports of safe use in pregnancy – Patients may need RBCs, renal replacement therapy Diseases specific to pregnancy Major treatment = fetus delivery • Pre-eclampsia (3-14% of all pregnancies). Most common in first pregnancy (with same partner) – HTN (140/90) and proteinuria after 20 weeks (HAs, rapid weight gain, limb edema) – Defect of trophoblasts to express adhesion molecules, VEGFs and their receptors – Feto-placental ischemia develops • HELLP (0.5-0.9% of pregnancies). Fall in plt count often precedes LFTs abnormalities – Early presenting signs include shoulder/neck, upper body pain, malaise, N/V, HA – Smear can be similar to TTP (but in TTP, usually don’t see liver derangement). • Send ADAMTS13 (which will be normal/slightly depressed) • AFLDP (5/100,000 pregnancies). DIC is the hallmark; microvesicular steatosis of liver biopsy – Maternal mortality 18%; fetal mortality 23% – AST/ALT can be 1000: RUQ/epigastric pain, coagulopathy, N/V, headache – Maternal heterozygote for long chain 3 hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) . Worse if maternal heterozygote is carrying fetal homozygote – Maternal liver disease may not be reversible Case 2, management • ADAMTS13: <5% – Inhibitor assay negative • Admitted to obstetrics: – Platelets normalized after 2 PLEX sessions – HCT continued to fall, despite normalization of lytic parameters – Ab CT was negative for RP bleed – Inappropriate response to RBC transfusion – Ultimately delivered via emergent cesarean on hospital day 7 for fetal distress • Placental abruption evident during surgery • Live male born with mild respiratory distress; normal platelet count The best way to decrease the risk for recurrent TTP in future pregnancies in this patient is: A. A course of rituximab once stabilized postpartum B. Use of aspirin in future pregnancies C. Plan to initiate PLEX in future pregnancies D. Plan for simple FFP transfusion in future pregnancies Pregnancy-Associated TTP • Increased risk of flare due to increased VWF • This patient had no demonstrated anti-ADAMTS13 antibody – Congenital TTP (cTTP); Upshaw Shulman Syndrome • Recurrent thrombocytopenia with microangiopathic hemolytic anemia • Onset: half first 2 years; half > 20 years • Once symptoms start, rarely stop • Precipitants: etoh, pregnancy, surgery • Chronic sequelae: renal, neurological, accelerated atherosclerosis (mice) Upshaw-Schulman
Load more

Recommended publications
  • I, Paul Knoebl
    Knoebl 2020-12-09 Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts Public declaration of interests I, Paul Knoebl Organisation/Company: Medical University of Vienna Country: Austria do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below: 2.1 Employment No interest declared 2.2 Consultancy Period Company Products Therapeutic Indication 01/2009-(current) Novo Nordisk acquired hemophilia, congenital hemophilia, rare bleeding disorders 01/2012-02/2019 Baxalta (now Shire) thrombotic thrombocytopenic purpura purpura fulminans acquired hemophilia 01/2012-01/2016 Alexion thrombotic microangiopathy 03/2010-07/2018 Ablynx thrombotic microangiopathy 07/2018-(current) Sanofi Genzyme thrombotic microangiopathy 02/2019-(current) Takeda thrombotic microangiopathy Acquired hemophilia 2.3 Strategic advisory role No interest declared 2.4 Financial interests Classified as public by the European Medicines Agency DOI Form Version-number: 4 Knoebl 2020-12-09 2 No interest declared 2.5 Principal investigator Period Company Products Therapeutic Indication 01/2013-(current) Baxalta, then Shire, now Takeda BAX930 Upshaw Schulman Syndrome 01/2013-(current) Novo Nordisc Concizumab Hemophilia 09/2010-04/2014 Gilead Ambisome fungal infections 09/2010-04/2014 MSD Posaconazol fungal infections 03/2010-(current) Ablynx caplacizumab thrombotic thrombocytopenic purpura 04/2010-01/2012
    [Show full text]
  • Extensive Purpura and Necrosis of the Leg
    PHOTO CHALLENGE Extensive Purpura and Necrosis of the Leg Michael Musharbash, MD; Lida Zheng, MD; Lauren Guggina, MD A 57-year-old woman presented with expanding purpura on the left leg of 2 weeks’ duration following a recent hema- topoietic stem cell transplant for refractory diffuse large B-cell lymphoma. Prior to dermatologic consultation, the patient had been hospitalizedcopy for 2 months following the transplant due to Clostridium difficile colitis, Enterococcus faecium bactere- mia, cardiac arrest, delayed engraftment with pancytopenia, and atypical hemolytic uremic syndrome with acute renal failure requiring hemodialysis and treatment with eculizumab. Hernot care team in the hospital initially noticed a small purpuric lesion on the posterior aspect of the left knee. The patient subsequently developed persistent fevers and expansion of the lesion, which prompted consultation of the dermatology ser- vice. Physical examination revealed a 22×10-cm, rectangular, indurated, purpuric plaque with central dusky, violaceous to black necrosis with superficial skin sloughing and peripheral dusky erythema extending from the inner thigh to the lower leg. The left distal leg felt cool, and both dorsalis pedis and posterior tibial pulses were absent. Laboratory test results revealed neutropenia and thrombocytopenia 3 3 Do 3 3 (white blood cell count, 0.2×10 /mm [reference range, 5–10×10 /mm ]; hematocrit, 23.2% [reference range, 41%–50%]; platelet count, 105×103/µL [reference range, 150–350×103/µL]). A punch biopsy was performed. WHAT’S THE DIAGNOSIS? a. disseminated aspergillosis b. disseminated intravascular coagulation c. disseminated mucormycosis d. purpura fulminans e. pyodermaCUTIS gangrenosum PLEASE TURN TO PAGE E2 FOR THE DIAGNOSIS From the Department of Dermatology, Northwestern Memorial Hospital, Chicago, Illinois.
    [Show full text]
  • Warfarin-Induced Skin Necrosis Due to Protein C Deficiency in a Dialysis Patient Diyaliz Hastasında Protein C Eksikliğine Bağlı Warfarin-İlişkili Deri Nekrozu
    doi: 10.5262/tndt.2018.2775 Case Report/Olgu Sunumu Warfarin-Induced Skin Necrosis Due to Protein C Deficiency in a Dialysis Patient Diyaliz Hastasında Protein C Eksikliğine Bağlı Warfarin-İlişkili Deri Nekrozu ABSTRACT Abdullah ÖZKÖK1 Hande ÖZPORTAKAL1 Protein-C (PC) is a vitamin-K-dependent anticoagulant proenzyme produced by the liver. PC deficiency Murat AŞIK2 may cause both venous and arterial thromboses. In patients with PC deficiency, warfarin further 2 decreases PC activity and causes thrombosis of skin arterioles leading to skin necrosis. Serçin ÖZKÖK Özlem ALKAN1 A 59-year-old female was admitted with dyspnea, cough, hoarseness and edema in her neck and arms. Memduha BOYRAZ1 She had chronic kidney disease for 20 years. She had been on hemodialysis for 8 years but had been Gökhan GÖNENLI3 switched to peritoneal dialysis due to vascular access problems caused by multiple venous thromboses. Banu ŞAHIN YILDIZ1 With a pre-diagnosis of Superior Vena Cava (SVC) syndrome, cavography was performed and near- Kübra AYDIN BAHAT1 total occlusion of the SVC was detected. Balloon dilatation was performed and warfarin 5 mg and Ali Rıza ODABAŞ1 enoxoparin 40 mg were started. Within a day, necrotic and well-demarcated lesions 4x5 cm in size appeared on the arm. Warfarin was stopped and enoxoparin was continued. After 2 weeks, plasma PC activity was found to be significantly low (40% of normal). The diagnosis of “warfarin-induced skin necrosis in a patient with PC deficiency” was established. Skin lesions promptly and completely recovered after the treatment. 1 Istanbul Medeniyet University, PC deficiency should be considered in dialysis patients with multiple thromboses, vascular access Goztepe Training and Research Hospital, problems and warfarin-induced skin necrosis.
    [Show full text]
  • PROTEIN C DEFICIENCY 1215 Adulthood and a Large Number of Children and Adults with Protein C Mutations [6,13]
    Haemophilia (2008), 14, 1214–1221 DOI: 10.1111/j.1365-2516.2008.01838.x ORIGINAL ARTICLE Protein C deficiency N. A. GOLDENBERG* and M. J. MANCO-JOHNSON* *Hemophilia & Thrombosis Center, Section of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Colorado Denver and The ChildrenÕs Hospital, Aurora, CO; and Division of Hematology/ Oncology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA Summary. Severe protein C deficiency (i.e. protein C ment of acute thrombotic events in severe protein C ) activity <1 IU dL 1) is a rare autosomal recessive deficiency typically requires replacement with pro- disorder that usually presents in the neonatal period tein C concentrate while maintaining therapeutic with purpura fulminans (PF) and severe disseminated anticoagulation; protein C replacement is also used intravascular coagulation (DIC), often with concom- for prevention of these complications around sur- itant venous thromboembolism (VTE). Recurrent gery. Long-term management in severe protein C thrombotic episodes (PF, DIC, or VTE) are common. deficiency involves anticoagulation with or without a Homozygotes and compound heterozygotes often protein C replacement regimen. Although many possess a similar phenotype of severe protein C patients with severe protein C deficiency are born deficiency. Mild (i.e. simple heterozygous) protein C with evidence of in utero thrombosis and experience deficiency, by contrast, is often asymptomatic but multiple further events, intensive treatment and may involve recurrent VTE episodes, most often monitoring can enable these individuals to thrive. triggered by clinical risk factors. The coagulopathy in Further research is needed to better delineate optimal protein C deficiency is caused by impaired inactiva- preventive and therapeutic strategies.
    [Show full text]
  • ADAMTS13 in Arterial Thrombosis
    ADAMTS13 in Arterial Thrombosis Tamara Bongers ADAMTS13 in Arterial Thrombosis © 2010 Tamara Bongers, Rotterdam, The Netherlands No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission from the author or, when appropriate, from publishers of the publications. ISBN: 978-90-9025798-3 Cover design: Tamara Bongers Layout: Henri Wijnbergen and Tamara Bongers Printing: Ipskamp Drukkers, Enschede ADAMTS13 in Arterial Thrombosis ADAMTS13 in arteriële trombose Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op donderdag 9 december 2010 om 11:30 uur door Tamara Natascha Bongers geboren te Zevenaar Promotiecommissie Promotor: Prof.dr. F.W.G. Leebeek Overige leden: Prof.dr. M.M.B. Breteler Prof.dr. D.W.J. Dippel Dr. T. Lisman Copromotor: Dr. M.P.M. de Maat The work described in this thesis was performed at the Deparment of Hematology of Erasmus University Medical Center, Rotterdam, The Nether- lands. This work was partly funded by MRACE Translational Research Grant ErasmusMC 2004 as a clinical fellow to F.W.G. Leebeek. Financial support by the Netherlands Heart Foundation for publication of this thesis is gratefully acknowledged. Printing of this thesis was financially supported by Baxter, Erasmus University Rotterdam, Jurriaanse Stichting, Kordia and Pfizer. “ The World is a book, and
    [Show full text]
  • Sepsis-Associated Disseminated Intravascular Coagulation and Its
    Iba et al. Journal of Intensive Care (2019) 7:32 https://doi.org/10.1186/s40560-019-0387-z REVIEW Open Access Sepsis-associated disseminated intravascular coagulation and its differential diagnoses Toshiaki Iba1* , Eizo Watanabe2,3, Yutaka Umemura4, Takeshi Wada5, Kei Hayashida6, Shigeki Kushimoto7, Japanese Surviving Sepsis Campaign Guideline Working Group for disseminated intravascular coagulation and Hideo Wada8 Abstract Disseminated intravascular coagulation (DIC) is a common complication in sepsis. Since DIC not only promotes organ dysfunction but also is a strong prognostic factor, its diagnosis at the earliest possible timing is important. Thrombocytopenia is often present in patients with DIC but can also occur in a number of other critical conditions. Of note, many of the rare thrombocytopenic diseases require prompt diagnoses and specific treatments. To differentiate these diseases correctly, the phenotypic expressions must be considered and the different disease pathophysiologies must be understood. There are three major players in the background characteristics of thrombocytopenia: platelets, the coagulation system, and vascular endothelial cells. For example, the activation of coagulation is at the core of the pathogenesis of sepsis-associated DIC, while platelet aggregation is the essential mechanism in thrombotic thrombocytopenic purpura and endothelial damage is the hallmark of hemolytic uremic syndrome. Though each of the three players is important in all thrombocytopenic diseases, one of the three dominant players typically establishes the individual features of each disease. In this review, we introduce the pathogeneses, symptoms, diagnostic measures, and recent therapeutic advances for the major diseases that should be immediately differentiated from DIC in sepsis. Keywords: Disseminated intravascular coagulation, Sepsis, Thrombotic thrombocytopenic purpura, Hemolytic uremic syndrome, Heparin-induced thrombocytopenia Background outcome in patients with sepsis [3].
    [Show full text]
  • The Varicella-Autoantibody Syndrome
    0031-3998/01/5003-0345 PEDIATRIC RESEARCH Vol. 50, No. 3, 2001 Copyright © 2001 International Pediatric Research Foundation, Inc. Printed in U.S.A. The Varicella-Autoantibody Syndrome CASSANDRA JOSEPHSON, RACHELLE NUSS, LINDA JACOBSON, MICHELE R. HACKER, JAMES MURPHY, ADRIANA WEINBERG, AND MARILYN J. MANCO-JOHNSON Departments of Pediatrics [C.J., R.N., L.J., M.R.H., A.W., M.J.M.-J.] and Preventive Medicine and Biometrics [J.M.], University of Colorado Health Sciences Center, Denver, Colorado 80262, U.S.A., and The Children’s Hospital, Denver, Colorado 80218, U.S.A. [C.J., R.N., L.J., M.R.H., A.W., M.J.M.-J.] ABSTRACT This cross-sectional study was conducted to determine the increased PS IgG antibody (p Ͻ 0.001) compared with the incidence of autoantibodies to phospholipids and coagulation children without acute VZV. For all groups combined, elevated proteins in children with acute varicella zoster virus (VZV) PS IgG antibody showed negative correlation with free PS (p Ͻ infection. Study groups included children with VZV alone or 0.0001) and positive correlation with prothrombin fragment 1ϩ2 complicated by purpura fulminans and/or thromboembolism. (p ϭ 0.0002). Autoantibodies were transient. Transient antiphos- VZV naïve children and children who had VZV Ͼ1 y before pholipid and coagulation protein autoantibodies were common sample collection formed a control group. Blood was assayed for with VZV infection, but were not predictive of thrombotic the following: free protein S (PS), protein C, antithrombin, and complications. (Pediatr Res 50: 345–352, 2001) prothrombin; antibody binding to these proteins; lupus anticoag- ulant; anticardiolipin antibody; antiphospholipid antibodies; and Abbreviations prothrombin fragment 1ϩ2.
    [Show full text]
  • Neonatal Hematology
    Neonatal Hematology Tung Wynn, MD April 28, 2016 Disclosures • I am site principal investigator for Baxalta, Novonordisk, Bayer, and AstraZeneca studies Hemophilia Factor VIII Def Protein C Def Factor IX Def Protein S Def Rare factor deficiencies Antithrombin III Def Factor XIII Factor V Leiden Mut Factor VII Prothrombin Mut Von Willebrands AntiPhospholipids Antibodies Thrombocytopenia Hyperhomocysteinemia Platelet dysfunctions MTHFR mutations Liver Disease Factor VIII elevation Vitamin K deficiency Liver Disease Afibrinogenemia Vitamin K deficiency Dysfibrinogenemia Dysfibrinogenemia Alpha-2 antiplasmin Def Plasminogen activator inhibitor-1 mut Plasminogen activator Inhibitor-1 Def Coagulation Anti-Coagulation Overview • Three phases of Coagulation – Vascular phase – Platelet phase • Platelet adhesion • Platelet aggregation – Coagulation phase • Intrinsic pathway • Extrinsic pathway • Clot contraction • Activation of coagulation also initiates the process of fibrinolysis Neonatal Hemostatic System Differences Coagulation Anticoagulation – Factor II – Plasminogen – Factor VII – Antithrombin III – Factor IX – Protein C – Factor X – Protein S – Factor XI – Factor XIII – Platelet levels are normal, but have wider variability Physiologic “deficiencies” of both coagulation and anticoagulation “balance” each other out in the neonate. General Approach to Neonatal bleeding • History – Fever – PPROM – Chorioamnonitis – Fetal Distress – Birth Trauma – Maternal infection – Maternal CBC – Family history autoimmune disease, coagulation disorder, low
    [Show full text]
  • Primary Catastrophic Antiphospholipid Syndrome in an 8 Year-Old- Girl
    Marmara Medical Journal 2016; 29: 41-44 DOI: 10.5472/MMJcr.2901.07 CASE REPORT / OLGU SUNUMU Primary catastrophic antiphospholipid syndrome in an 8 year-old- girl Primer katastrofik antifosfolipid sendrom: 8 yaşında kız çocuk Hatice Ezgi BARIS, Cisem AKSU LIMON, Irmak VURAL, Eda KEPENEKLİ, Ahmet KOC, Ayca KIYKIM, Deniz YUCELTEN, Ozgur KASAPCOPUR, Safa BARIS, Elif KARAKOC-AYDINER, Ahmet OZEN, Isil BARLAN ABSTRACT ÖZ Antiphospholipid syndrome (APS) is a disease characterized by Antifosfolipid antikor sendromu (AFAS) tekrarlayan venöz ve recurrent arterial and venous thromboses. Rapidly progressive arteriyel trombozlarla seyreden bir hastalıktır. Hastaların %1’inden multiple thromboses leading to multiorgan failure occur in less azında görülen hızlı seyirli, çoklu trombozlara bağlı multiorgan than 1% of patients and named as catastrophic antiphospholipid yetmezlik tablosu katastrofik antifosfolipid antikor sendromu syndrome (CAPS). We, hereby, describe an 8 year-old-girl with (KAFAS) olarak adlandırılmaktadır. Burada eritematöz cilt erythematous skin lesions progressing into purpura fulminans. The lezyonlarıyla başvuran, takibinde alt ekstremitelerde yaygın purpura patient developed CAPS with the findings including proteinuria, fulminans gelişen 8 yaşında kız çocuk sunulmaktadır. Hastada microangiopathic hemolytic anemia, thrombocytopenia, arterial cilt tutulumuna ek olarak izlemde proteinüri, mikroanjiyopatik and venous thromboses demonstrated on skin biopsies. She was hemolitik anemiye eşlik eden trombositopeni gelişmesi ve cilt admitted to intensive care unit and received empirical antibiotics, biyopsilerinde arteryel ve venöz trombozlar gösterilmesi nedeniyle anticoagulants, antiaggregants, steroids and intravenous KAFAS geliştiği düşünüldü. Hastaya yoğun bakım desteği ve immunoglobulins. The diagnosis of APS was confirmed by geniş spektrumlu antimikrobiyal tedavilerin yanısıra antikoagulan, positive lupus anticoagulants, elevated anti beta-2 glycoprotein IgG antiagregan, steroid, intravenöz immünoglobulin tedavileri and antiphospholipid IgG titers.
    [Show full text]
  • 1 Natural History of Coagulopathy and Use Of
    NATURAL HISTORY OF COAGULOPATHY AND USE OF ANTI-THROMBOTIC AGENTS IN COVID-19 PATIENTS AND PERSONS VACCINATED AGAINST SARS-COV-2 Principal Investigators Prof Dani Prieto-Alhambra (University of Oxford) Associate Prof Katia Verhamme (EMC) Associate Prof Peter Rijnbeek (EMC) Document Status Date of final version of the study Protocol ver 1.1 report EU PAS register number EUPAS40414 1 PASS information Title Natural history of coagulopathy and use of anti-thrombotic agents in COVID-19 patients and persons vaccinated against SARS-CoV-2 Protocol version identifier 1.1 Date of last version of protocol 07/06/2021 EU PAS register number EUPAS40414 Active Ingredient n/a Medicinal product J07BX Product reference n/a Procedure number n/a Marketing authorisation holder(s) n/a Joint PASS n/a Research question and objectives 1) To estimate the background incidence of selected embolic and thrombotic events of interest among the general population. 2) To estimate the incidence of selected embolic and thrombotic events of interest among persons vaccinated against SARS-CoV-2 at 7, 14, 21, and 28 days. 3) To estimate incidence rate ratios for selected embolic/thrombotic events of interest amongst people vaccinated against SARS-CoV-2 compared to background rates as estimated in Objective #1. 4) To estimate the incidence of venous thromboembolic events among patients with COVID-19 at 30-, 60-, and 90-days. 5) To calculate the risks of COVID-19 worsening stratified by the occurrence of a venous thromboembolic event. 6) To assess the impact of risk factors on the rates of venous thromboembolic events among patients with COVID-19.
    [Show full text]
  • Trauma Induced Adult Purpura Fulminans: a Case Report Deepa Durga Roy Senior Resident, Safdarjung Hospital & V.M.M
    Case Report DOI: 10.18231/2394-6776.2018.0047 Trauma induced adult purpura fulminans: A case report Deepa Durga Roy Senior Resident, Safdarjung Hospital & V.M.M. College, New Delhi, India *Corresponding Author: Email: [email protected] Abstract Introduction: Purpura fulminans is characterised by sudden and rapid advancement of hematologic and cutaneous manifestations in the form of skin necrosis and disseminated intravascular coagulation which progresses to multi organ failure resulting in death if left unidentified. Even as neonatal purpura is popularly documented, there is paucity of literature regarding adult purpura fulminans which may occur secondary to sepsis, be an autoimmune response or be of idiopathic origin. Autopsy findings are usually negative. The following case is of a young healthy army man who died suddenly of purpura fuminans consequent to a single lacerated injury sustained to lower limb. Keywords: Purpura, Purpura fulminans, Adult, Injury, Trauma. Introduction opening the stitches the lacerated wound was muscle Henoch in 1887 introduced the term purpura deep. Margins of the wound were clean. The whole body fuminans. The condition refers to rapidly progressing, (more over the lower limbs) showed widespread non life threatening, widespread, dermal microvascular blanching reddish purple purpuric rash, which was thrombosis associated with disseminated intravascular showing bluish black hemmorhagic necrosis at places coagulation (DIC) and perivascular hemorrhage with diffuse margins, which on cut section revealed characterised by non-blanch able hemorrhagic skin necrosis up to subcutaneous tissue. On internal lesions. Purpura fuminans in neonates or children may examination florid petechaie were present in heart, liver occur in severe acute sepsis and is an important feature and both lungs.
    [Show full text]
  • A Baby with Bruises / Holland and Ciener • Vol
    Abstract: A 7-day-old female infant presented to the emergency department with a chief complaint of bruises. She was found to have severe coagulopathy. A Baby With Initial management focused on identifying and treating complica- tions of the coagulopathy without Bruises causing harm to the patient. Further workup was performed with the assistance of hematology experts to determine the underlying cause. Ultimately, the patient's diagnosis Jaycelyn R. Holland, MD, was determined by a single labora- tory test. This patient's presentation Daisy A. Ciener, MD allows us to review the workup of neonatal coagulopathy with special 1-week-old former 37-week female infant presented to attention to potential pitfalls one the emergency department (ED) with a chief complaint might encounter in the management of bruising for 5 days. She was discharged home from of these patients. the newborn nursery on day of life 2. The next day, the A “ ” mother noted a spot on her left leg that resembled a bruise. As Keywords: this first lesion was on her thigh, the mother attributed it to the hepatitis B and vitamin K intramuscular injections she received in neonatal coagulopathy; galactose- the nursery. Over the following days, she began to develop similar mia; newborn screen lesions on her legs, feet, and buttocks. On the day of admission, she was referred to the ED for further evaluation by her pediatrician because of continued spread of the lesions. The mother reported that the baby had otherwise seemed “normal.” She had not measured her temperature since they left the hospital but had not noted the baby feeling warm or cool to touch.
    [Show full text]